Anebulo Pharmaceuticals, Inc.

NasdaqCM ANEB

Anebulo Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -7.92 M

Anebulo Pharmaceuticals, Inc. Net Income is USD -7.92 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 31.41% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • Anebulo Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -11.55 M, a -46.63% change year over year.
  • Anebulo Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -7.88 M, a 75.04% change year over year.
  • Anebulo Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -31.55 M.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
Loading...
NasdaqCM: ANEB

Anebulo Pharmaceuticals, Inc.

CEO Mr. Richard Anthony Cunningham
IPO Date May 7, 2021
Location United States
Headquarters 1415 Ranch Road 620 South
Employees 2
Sector Health Care
Industries
Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Similar companies

OPT

Opthea Limited

USD 3.82

6.70%

ADAG

Adagene Inc.

USD 1.80

1.12%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

ANTX

AN2 Therapeutics, Inc.

USD 1.22

-3.17%

AVTE

Aerovate Therapeutics, Inc.

USD 2.47

-1.20%

ACRV

Acrivon Therapeutics, Inc. Common Stock

USD 5.56

0.91%

PMVP

PMV Pharmaceuticals, Inc.

USD 1.35

-2.88%

ANAB

AnaptysBio, Inc.

USD 14.91

1.98%

StockViz Staff

January 15, 2025

Any question? Send us an email